A groundbreaking study Presented at the 2023 Annual Meeting of the American Psychiatric Association San Francisco, CA, demonstrates that esketamine nasal spray can rapidly reduce depressive symptoms in adolescents at high risk of suicide. 

Unlike previous antidepressant trials, this study includes a vulnerable patient population that has been traditionally overlooked: adolescents at immediate and imminent risk of suicide. These findings contribute to our understanding of the potential benefits of esketamine and highlight the importance of inclusivity in clinical trials to address the needs of all patient groups. This study was conducted on male or female teenagers between the ages of 12 and 18 who had been diagnosed with Major Depressive Disorder. 

The results of this study revealed a meaningful improvement in depressive symptoms, which was both statistically and clinically significant, observed just 24 hours after the initial administration of pooled Esketamine doses at 56 mg and 84 mg. In comparison to a psychoactive comparator, the use of esketamine demonstrated a clear advantage in alleviating depressive symptoms. Treatment with a psychological intervention (individual cognitive behavioral therapy, interpersonal therapy, family

therapy, psychodynamic psychotherapy) was also required, at least through the initial 8-week Post-Treatment Follow-Up phase.

These findings provide substantial evidence supporting the efficacy of esketamine as a potential treatment option for individuals struggling with depression. By showcasing its rapid action and significant impact, this study contributes to our understanding of the therapeutic potential of esketamine and highlights its superiority over existing psychoactive comparators.

This study indicated that the adolescents experienced a rapid decrease in depressive symptoms, which aligns with similar findings observed in phase 3 studies involving adults with Major Depressive Disorder (MDD) who were dealing with acute suicidal thoughts or behavior. It is noteworthy that there were no new or unexpected safety concerns identified in the adolescent participants, and these observations were consistent with previous trials conducted with adults at risk of suicide. 

These conclusions provide further evidence supporting the effectiveness and safety of the treatment across different age groups, highlighting its potential as a valuable intervention in addressing depression and reducing the risk of suicide in both adolescents and adults with MDD.

Here at Blue Umbrella, we proudly offer Spravato (EsKetamine) as a form of treatment for suicidal ideation. We have seen tremendous improvement in multiple dire cases and are excited to share this innovative and effective treatment option with the community.

References:

Colette Kosik-Gonzalez

MA1

Dong Jing Fu

MD, PhD1*

Li "Nancy" Chen

PhD1

Rosanne Lane

MAS1

Wayne C. Drevets

MD2

Carla M. Canuso

MD1

Janssen Research and Development, LLC

Titusville, NJ | San Diego, CA

Esketamine Nasal Spray versus Psychoactive Comparator for Rapid Reduction of Depressive Symptoms in adolescents at Imminent Suicide Risk, 2023